免疫性疾病相关主动脉病变诊疗进展

doi:10.6040/j.issn.1671-7554.0.2024.0375

摘要/Abstract

摘要： 免疫性疾病相关主动脉病变一直是血管外科中充满挑战的病变,其主要表现为主动脉阻塞性或扩张性改变,从而引发脏器、肢体缺血或瘤体破裂致死风险。既往对于引发该类主动脉病变的免疫原发病诊断缺乏特异性,可能导致疾病综合管理方面的不足。本文从诊断和治疗两个方面分别诠释了常见免疫性疾病相关主动脉病变(大动脉炎、巨细胞动脉炎、白塞病)临床管理现状,并给出当前治疗不同类型主动脉病变的推荐方案,以期为临床工作和该领域未来发展提供参考。

关键词: 主动脉疾病, 免疫疾病, 开放手术, 腔内血管重建

Abstract: Immune-related aortic disease has always been a challenging lesion in vascular surgery, characterized by obstructive or dilated lesions in the aorta, leading to ischemia of organs and limbs, as well as the high mortality risk from aneurysm rupture. Previously, there was a lack of specificity in the diagnosis of the immune diseases that cause such aortic lesions, which may result in deficiencies in the comprehensive management of the disease. With the development of medical science, the management of this disease has been significantly improved, but its research progress still needs to be systematically summarized. This review aims to conclude the current status of the management for common immune-related aortic diseases(Takayasus aortitis, giant cell arteritis, Behcets arteritis)from diagnosis and therapy perspectives, and to provide recommendations for different types of aortic lesions, as well as to guide clinical work and future development in this field.

Key words: Aortic disease, Immunological disease, Open surgery, Endovascular revascularization

中图分类号:

R654.3

高健峰,李方达,吴亮霖,曾嵘,郑月宏. 免疫性疾病相关主动脉病变诊疗进展[J]. 山东大学学报 (医学版), 2024, 62(9): 30-35.

GAO Jianfeng, LI Fangda, WU Lianglin, ZENG Rong, ZHENG Yuehong. Progress in diagnosis and treatment of immune disease related aortic lesions[J]. Journal of Shandong University (Health Sciences), 2024, 62(9): 30-35.

参考文献

[1] Kadian-Dodov D, Seo P, Robson PM,et al. Inflammatory diseases of the aorta: JACC focus seminar, part 2[J]. J Am Coll Cardiol, 2022, 80(8): 832-844.
[2] Gravanis MB. Giant cell arteritis and Takayasu aortitis: morphologic, pathogenetic and etiologic factors[J]. Int J Cardiol, 2000, 75(1): 21-33.
[3] Saadoun D, Vautier M, Cacoub P. Medium- and large-vessel vasculitis[J]. Circulation, 2021, 143(3): 267-282.
[4] Zhang X, Li Y, Zheng YH. Diffuse aortoiliac occlusion with formation of extensive collateral circulation in Takayasus arteritis[J]. Eur Heart J, 2019, 40(41): 3439. doi:10.1093/eurheartj/ehz289.
[5] Joseph G, Goel R, Thomson VS, et al. Takayasu arteritis: JACC focus seminar 3/4[J]. J Am Coll Cardiol, 2022: S0735-S1097(22)07305-3. doi:10.1016/j.jacc.2022.09.051.
[6] Soulages A, Sibon I, Vallat JM, et al. Neurologic manifestations of giant cell arteritis[J]. J Neurol, 2022, 269(7): 3430-3442.
[7] Kaymakci MS, Boire NA, Bois MC, et al. Persistent aortic inflammation in patients with giant cell arteritis[J]. Autoimmun Rev, 2023, 22(9): 103411. doi:10.1016/j.autrev.2023.103411.
[8] Ishikawa K. Diagnostic approach and proposed criteria for the clinical diagnosis of Takayasus arteriopathy[J]. J Am Coll Cardiol, 1988, 12(4): 964-972.
[9] de Souza AWS, de Carvalho JF. Diagnostic and classification criteria of Takayasu arteritis[J]. J Autoimmun, 2014, 48/49: 79-83. doi:10.1016/j.jaut.2014.01.012.
[10] Ponte C, Grayson PC, Robson JC, et al. 2022 American College of Rheumatology/EULAR classification criteria for giant cell arteritis[J]. Ann Rheum Dis, 2022, 81(12): 1647-1653.
[11] Ben-Shoshan J, Zahler D, Steinvil A, et al. Extracranial carotid artery stenosis and outcomes of patients undergoing transcatheter aortic valve replacement[J]. Int J Cardiol, 2017, 227: 278-283. doi:10.1016/j.ijcard.2016.11.107.
[12] Li J, Wang YH, Wang YH, et al. Association between acute phase reactants, interleukin-6, tumor necrosis factor-α, and disease activity in Takayasus arteritis patients[J]. Arthritis Res Ther, 2020, 22(1): 285. doi:10.1186/s13075-020-02365-y.
[13] Andel PM, Chrysidis S, Geiger J, et al. Diagnosing giant cell arteritis: a comprehensive practical guide for the practicing rheumatologist[J]. Rheumatol Oxf Engl, 2021, 60(11): 4958-4971.
[14] Quinn KA, Ahlman MA, Malayeri AA, et al. Comparison of magnetic resonance angiography and 18F-fluorodeoxyglucose positron emission tomography in large-vessel vasculitis[J]. Ann Rheum Dis, 2018, 77(8): 1165-1171.
[15] Bardi M, Diamantopoulos AP. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice summary[J]. Radiol Med, 2019, 124(10): 965-972.
[16] 蔡丹杰, 迪丽比热·阿迪力, 石洪成. 18F-FDG全身PET/CT 2小时显像探测大动脉炎病灶的价值[J]. 中华核医学与分子影像杂志, 2022, 42(8): 462-466. CAI Danjie, Dilibire Adili, SHI Hongcheng. Value of 18F-FDG total-body PET/CT 2-hour imaging in detection of Takayasu arteritis[J]. Chinese Journal of Nuclear Medicine and Molecular Imaging, 2022, 42(8): 462-466.
[17] Badawi RD, Shi HC, Hu PC, et al. First human imaging studies with the EXPLORER total-body PET scanner[J]. J Nucl Med, 2019, 60(3): 299-303.
[18] 姜林娣,马莉莉,薛愉,等.大动脉炎诊疗规范[J].中华内科杂志, 2022, 61(5): 517-524. JIANG Lindi, MA Lili, XUE Yu, et al. Recommendations of diagnosis and treatment of Takayasus arteritis in China[J]. Chinese Journal of Internal Medicine, 2022, 61(5): 517-524.
[19] Monti S, águeda AF, Luqmani RA, et al. Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis[J]. RMD Open, 2019, 5(2): e001003. doi:10.1136/rmdopen-2019-001003.
[20] Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis[J]. Ann Rheum Dis, 2020, 79(1): 19-30.
[21] Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of giant cell arteritis and takayasu arteritis[J]. Arthritis Rheumatol, 2021, 73(8): 1349-1365.
[22] Kwon OC, Oh JS, Park MC, et al. Statins reduce relapse rate in Takayasu arteritis[J]. Int J Cardiol, 2019, 287: 111-115. doi:10.1016/j.ijcard.2019.02.046.
[23] Espitia O, Bruneval P, Assaraf M, et al. Long-term outcome and prognosis of noninfectious thoracic aortitis[J]. J Am Coll Cardiol, 2023, 12, 82(11): 1053-1064.
[24] Chaigne-Delalande S, de Menthon M, Lazaro E, et al. Giant-cell arteritis and Takayasu arteritis: epidemiological, diagnostic and treatment aspect s[J]. Presse Med, 2012, 41(10): 955-65.
[25] Peng M, Ji W, Jiang X, et al. Selective stent placement versus balloon angioplasty for renovascular hypertension caused by Takayasu arteritis: Two-year results[J]. Int J Cardiol, 2016, 15, 205: 117-123. doi:10.1016/j.ijcard.2015.12.006.
[26] Gülcü A, Gezer NS, Akar S, et al. Long-term follow-up of endovascular repair in the management of arterial stenosis caused by Takayasus arteritis[J]. Ann Vasc Surg, 2017, 42: 93-100. doi:10.1016/j.avsg.2016.10.066.
[27] Jung JH, Lee YH, Song GG, et al. Endovascular versus open surgical intervention in patients with Takayasus arteritis: a meta-analysis[J]. Eur J Vasc Endovasc Surg, 2018, 55(6): 888-899.
[28] Isselbacher EM, Preventza O, Hamilton Black J 3rd, et al. 2022 ACC/AHA guideline for the diagnosis and management of aortic disease: a report of the American Heart Association/American College of Cardiology Joint Committee on clinical practice guidelines[J]. Circulation, 2022, 146(24): e334-e482.
[29] Mirouse A, Biard L, Comarmond C, et al. Overall survival and mortality risk factors in Takayasus arteritis: a multicenter study of 318 patients[J]. J Autoimmun, 2019, 96: 35-39. doi:1016/j.jaut.2018.08.001.
[30] Saadoun D, Lambert M, Mirault T, et al. Retrospective analysis of surgery versus endovascular intervention in Takayasu arteritis: a multicenter experience[J]. Circulation, 2012, 125(6): 813-819.
[31] Joseph G, Thomson VS, Attumalil TV, et al. Outcomes of percutaneous intervention in patients with Takayasu arteritis[J]. J Am Coll Cardiol, 2023, 81(1): 49-64.
[32] Espitia O, Bruneval P, Assaraf M, et al. Long-term outcome and prognosis of noninfectious thoracic aortitis[J]. J Am Coll Cardiol, 2023, 82(11): 1053-1064.
[33] Wu L, Li F, Sun X, et al. Long term outcomes and potential risk factors for endovascular repair of aortic pseudoaneurysms in vascular Behçets disease[J]. Eur J Vasc Endovasc Surg, 2023, 66(2): 169-177.
[34] International Study Group for Behçets Disease. Criteria for diagnosis of Behçets disease [J]. Lancet, 1990, 335(8697): 1078-1080.
[35] Kwon TW, Park SJ, Kim HK, et al. Surgical treatment result of abdominal aortic aneurysm in Behçets disease[J]. Eur J Vasc Endovasc Surg, 2008, 35(2): 173-180.
[36] Mousa A, Hanbal I, Sharabi A, et al. Vascular suture line wrapping for Aortoiliac anastomoses following open surgical repair of Infrarenal Behçets Aortoiliac aneurysms[J]. Orphanet J Rare Dis, 2019, 14(1): 81. doi:10.1186/s13023-019-1048-y.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed